Comparison of lenograstim and filgrastim on haematological effects after autologous peripheral blood stem cell transplantation with high-dose chemotherapy

References

• Shea TC. Introduction: current issues in high-dose chemotherapy and stem cell support. Bone Marrow Transplant 1999;23:S1–S5
   PubMed Web of Science ®Google Scholar
• Schmidt N, Linch DC, Dreger P, et al. Randomized trial of filgrastim-mobilized peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients. Lancet 1996; 347:353–7
   PubMed Web of Science ®Google Scholar
• Gillespie TW, Hillyer CD. Peripheral blood progenitor cells for marrow reconstitution: mobilization and collection strategies. Transfusion 1996;36:611–24
   PubMed Web of Science ®Google Scholar
• To LB, Roberts MM, Haylock DN, et al. Comparison of hematological recovery times and supportive care requirements of autologous phase peripheral blood stem cell transplants, autologous bone marrow transplants and allogeneic bone marrow transplants. Bone Marrow Transplant 1992;9:277–84
   PubMed Web of Science ®Google Scholar
• Beyer J, Schwella N, Zingsem J, et al. Hematopoietic rescue after high-dose chemotherapy using autologous peripheral-blood progenitor cells or bone marrow: a randomized comparison. J Clin Oncol 1995;13:1328–35
   PubMed Web of Science ®Google Scholar
• Hendon PR, Liang H, Beck-Wirth G, et al. Comparison of hematopoietic and immune recovery after autologous bone marrow or blood stem cell transplants. Bone Marrow Transplant 1992;9:285–91
   PubMed Web of Science ®Google Scholar
• Bearman SI, Appelbaum FR, Back, et al. Regimen-related toxicity and early post-transplant survival in patients undergoing marrow transplantation for lymphoma. J Clin Oncol 1989;7:1288–94
   PubMed Web of Science ®Google Scholar
• Bodey GP, Buckley M, Sathe YS, et al. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 1966;64:328–40
   PubMed Web of Science ®Google Scholar
• Schmitz N, Dreger P, Zander AR, et al. Results of randomized, controlled, multicentre study of recombinant human granulocyte colony-stimulating factor (filgrastim) in patients with Hodgkin’s disease and non-Hodgkin’s lymphoma undergoing autologous bone marrow transplantation. Bone Marrow Transplant 1995;15:261–6
   PubMed Web of Science ®Google Scholar
• Bensinger W, Singer J, Appelbaum F, et al. Autologous transplantation with peripheral blood mononuclear cells collected after administration of recombinant granulocyte colony-stimulating factor. Blood 1993;81:3158–63
   PubMed Web of Science ®Google Scholar
• Sheridan WP, Wolf M, Lusk J, et al. Granulocyte colony-stimulating factor and neutrophil recovery after high dose chemotherapy and autologous bone marrow transplantation in. Lancet 1989;2:891–5
   PubMed Web of Science ®Google Scholar
• Taylor KM, Jagannath S, Spitzer G, et al. Recombinant human granulocyte colony-stimulating factor hastens granulocyte recovery after high-dose chemotherapy and autologous bone marrow transplantation in Hodgkin’s disease. J Clin Oncol 1989;7:1791–9
   PubMed Web of Science ®Google Scholar
• Stahel RA, Jost LM, Cerny T, et al. Randomized study of recombinant human granulocyte colony-stimulating factors after high-dose chemotherapy and autologous bone marrow transplantation for high-risk lymphoid malignancies. J Clin Oncol 1994;12:1931–8
   PubMed Web of Science ®Google Scholar
• Nemunaitis J, Rabinowe SN, Singer JW, et al. Recombinant granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid cancer. N Engl J Med 1991;324:1773–8
   PubMed Web of Science ®Google Scholar
• Sheridan WP, Begley CG, Juttner CA, et al. Effect of peripheral-blood progenitor cells mobilized by filgrastim (G-CSF) on platelet recovery after high-dose chemotherapy. Lancet 1992;339:640–4
   PubMed Web of Science ®Google Scholar
• Socinski MA, Cannistra SA, Elias A, et al. Granulocyte-macrophage colony stimulating factor expands the circulating haemotopoietic progenitor cell compartment in man. Lancet 1988;1:1194–8
   PubMed Web of Science ®Google Scholar
• Vigorito AC, Azevedo WM, Marques JF, et al. A randomized, prospective comparison of allogeneic bone marrow and peripheral blood progenitor cell transplantation in the treatment of haematological malignancies. Bone Marrow Transplant 1998;22:1145–51
   PubMed Web of Science ®Google Scholar
• Chao NJ, Schriber JR, Grimes K, et al. Granulocyte colony-stimulating factor ‘mobilized’ peripheral blood progenitor cells accelerate granulocyte and platelet recovery after high-dose chemotherapy. Blood 1993;81:2031–5
   PubMed Web of Science ®Google Scholar
• Crawford J, Ozer H, Stoller R, et al. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 1991;325:164–70
   PubMed Web of Science ®Google Scholar
• Mostyn G, Burges AW. Hematopoietic growth factors: a review. Cancer Res 1988;48:5624–37
   PubMed Web of Science ®Google Scholar
• Lieschke GJ, Burgess AW. Granulocyte colony-stimulating factor and granulocyte macrophage colony-stimulating factor. N Engl J Med 1992;327: 28–35,99–106
   PubMed Web of Science ®Google Scholar
• Kubota N, Orita T, Hattori K. Structural characterization of natural and recombinant human granulocyte colony-stimulating factor. J Biochem 1990;107:486–92
   PubMed Web of Science ®Google Scholar
• Nissen C, Dalle Carbonare V, Moser Y. In vitro comparison of the biological potency of glycosylated versus nonglycosylated rGCSF. Drug Invest 1994;7:346–52
   Google Scholar
• Watts MJ, Addison I, Long SG, et al. Crossover study of the haematological effects and pharmacokinetics of glycosylated and non-glycosylated G-CSF in healthy volunteers. Br J Haematol 1997;98:474–9
   PubMed Web of Science ®Google Scholar
• Rebischung JN, Deletie E, Larroutourou P, et al. Comparative study of filgrastim and lenograstim. Clinical and economic studies. Proc Am Soc Clin Oncol 1994;14:260 (Abstr 713)
   Google Scholar
• Saccardi R, Avanzi G, Brzzini R, et al. Mobilization of PBPC for hematological rescue: comparison between glycosylated and nonglycosylated G-CSF. Bone Marrow Transplant 1997;19;S11(Suppl 1; Abstr 43)
   PubMed Web of Science ®Google Scholar
• Stahel RA, Jost LM, Honegger H, Betts E, Goebel MEM, Nagler A. Randomized trial showing equivalent efficacy of filgrastim 5 mg/kg/day and 10 mg/kg/day following high dose chemotherapy and autologous bone marrow transplantation in high-risk lymphomas. J Clin Oncol 1997;15:1730–5
   PubMed Web of Science ®Google Scholar